Renati Innovation S.A.P.I de C.V

Guadalajara, Jalisco 44680

2 studies enrolling now · 4 studies all time

What they study most

Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer

Studies at this site

• To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer — Recruiting now
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) — Recruiting now
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy — Running, not enrolling
• A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants — Completed